24R0002_JEV_JA_Final_SIGNED_Redacted.pdf

This is a limited source/sole source justification and approval (J&A) document for Japanese Encephalitis Vaccine (JEV) issued by the Defense Logistics Agency Troop Support Medical. The J&A authorizes a sole source award to Emergent BioSolutions for Contract SPE2DP-25-D-0002 for Japanese Encephalitis Vaccine, with a period of performance from January 29, 2025 through January 28, 2028 including all options.

The estimated total value is $34,491,600, with a base period of $11,497,200 and two 12-month option periods at $11,497,200 each. The J&A cites Emergent BioSolutions as the only FDA-licensed manufacturer of JE-Vax in the U.S., making them the sole responsible source capable of satisfying the agency's requirements. The vaccine is required to protect military personnel and other DoD beneficiaries against Japanese Encephalitis virus when deployed to endemic areas in Asia and the Western Pacific.